Efficacy of amlodipine in pediatric bone marrow transplant patients.

• Abstract: The calcium antagonist amlodipine may have the potential for expanded use in children owing to its physiochemistry and pharmacokinetic profile that facilitates once-daily dosing in a liquid formulation. Its safety and efficacy have not been previously evaluated in children. A retrospective analysis of 15 pediatric bone marrow transplant patients who had amlodipine incorporated into their antihypertensive drug regimen reveals significantly lower blood pressure as compared with baseline therapy (123.5+/-2.1 mmHg and 117.2+/-2.2 mmHg, systolic blood pressure before and during amlodipine, P<0.05; 81.5+/-1.8 mmHg and 75.5+/-2.6 mmHg, diastolic blood pressure before and during amlodipine, P<0.05). Amlodipine provided improved blood pressure control in this cohort and may provide a valuable pharmacologic alternative for treatment of pediatric hypertension.
• Authors: S Khattak, J W Rogan, E F Saunders, J G Theis, G S Arbus, G Koren (Affiliation: Division of Clinical Pharmacology and Toxicology, The Hospital for Sick Children, The University of Toronto, Ontario, Canada.)
• Journal: Clinical pediatrics (Clin Pediatr (Phila)) Vol. 37 Issue 1 Pg. 31-5 (Jan 1998) ISSN: 0009-9228 [Print] UNITED STATES
• PMID: 9475697 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Amlodipine

Topics

• Adolescent
• Age Factors
• Amlodipine (administration & dosage, pharmacokinetics)
• Bone Marrow Transplantation
• Child
• Child, Preschool
• Cohort Studies
• Female
• Humans
• Hypertension (drug therapy)
• Infant
• Kidney (drug effects)
• Male
• Postoperative Care